

Citations

1. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. *J Clin Psychopharmacol* 2001;21:335-339.
2. Levine J, Umansky R, Ezriev G, Belmaker RH. Lack of effect of inositol treatment in chronic schizophrenia. *Biol Psychiatry* 1993;33:673-675.
3. Jope RS, Song L, Grimes CA et al. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. *J Neurochem* 1998;70:763-771.
4. Levine J, Ring A, Barak Y et al. Inositol may worsen attention deficient disorder with hyperactivity. *Hum Psychopharmacol* 1995;10:481-484.
5. Levine J, Witztum E, Greenberg BD, Barak Y. Inositol-induced mania? *Am J Psychiatry* 1996;153:839.
6. Greene ND, Copp AJ. Inositol prevents folate-resistant neural tube defects in the mouse. *Nat Med* 1997;3:60-66.
7. Reece EA, Khandelwal M, Wu YK, Borenstein M. Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. *Am J Obstet Gynecol* 1997;176:536-539.
8. Phaneuf S, Europe-Finner GN, Carrasco MP et al. Oxytocin signalling in human myometrium. *Adv Exp Med Biol* 1995;395:453-467.
9. Chien EK, Saunders T, Phillippe M. The mechanisms underlying Bay K 8644-stimulated phasic myometrial contractions. *J Soc Gynecol Invest* 1996;3:106-112.
10. Colodny L, Hoffman RL. Inositol—clinical applications for exogenous use. *Altern Med Rev* 1998;3:432-447.
11. Kofman O, Belmaker RH. Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. *Biol Psychiatry* 1993;34:839-852.
12. Bersudsky Y, Einat H, Stahl Z, Belmaker RH. Epi-inositol and inositol depletion: two new treatment approaches in affective disorder. *Curr Psychiatry Rep* 1999;1:141-147.
13. Chengappa KN, Levine J, Gershon S et al. Inositol as an add-on treatment for bipolar depression. *Bipolar Disord* 2000;2:47-55.
14. Silverstone PH, Rotzinger S, Pukhovsky A, Hanstock CC. Effects of lithium and amphetamine on inositol metabolism in the human brain as measured by ¹H and ³¹P MRS. *Biol Psychiatry* 1999;46:1634-1641.
15. O'Donnell T, Rotzinger S, Nakashima TT et al. Chronic lithium and sodium valproate both decrease the concentration of myoinositol and increase the concentration of inositol monophosphates in rat brain. *Eur Neuropsychopharmacol* 2003;13:199-207.
16. Lee S. Side effects of chronic lithium therapy in Hong Kong Chinese: an ethnopsychiatric perspective. *Cult Med Psychiatry* 1993;17:301-320.
17. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. *J Psychiatry Neurosci* 2002;27:104-107.
18. Levine J, Sheckman T, Lefkifker E et al. Inositol may reverse lithium-induced polydipsia but not polyuria. *Hum Psychopharmacol* 1998;12:459-465.
19. Allan SJ, Kavanagh GM, Herd RM, Savin JA. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. *Br J Dermatol* 2004;150:966-969.
20. Benjamin J, Agam G, Levine J et al. Inositol treatment in psychiatry. *Psychopharmacol Bull* 1995;31:167-175.
21. Belmaker RH, Bersudsky Y, Benjamin J et al. Manipulation of inositol-linked second messenger systems as a therapeutic strategy in psychiatry. *Adv Biochem Psychopharmacol* 1995;49:67-84.
22. Belmaker RH, Bersudsky Y, Agam G et al. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. *Annu Rev Med* 1996;47:47-56.
23. Berridge M. Regulation of ion channels by inositol triphosphate and diacylglycerol. *J Exp Biol* 1986;323:323-335.
24. Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. *J Neural Transm* 1999;106:795-798.
25. Carey PD, Warwick J, Harvey BH et al. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. *Metab Brain Dis* 2004;19:125-134.
26. Levine J, Aviram A, Holan A et al. Inositol treatment of autism. *J Neural Transm* 1997;104:307-310.
27. Albert U, Bergesio C, Pessina E et al. Management of treatment resistant obsessive-compulsive disorder: algorithms for pharmacotherapy. *Panminerva Med* 2002;44:83-91.
28. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. *Int J Neuropsychopharmacol* 1999;2:193-195.
29. Zhou JR, Erdman JW Jr. Phytic acid in health and disease. *Crit Rev Food Sci Nutr* 1995;35:495-508.

Reference Literature

- Albert U, Bergesio C, Pessina E, et al. Management of treatment resistant obsessive-compulsive disorder: algorithms for pharmacotherapy. *Panminerva Med* 2002;44(2):83-91. (Review)
- Barak Y, Levine J, Glasman A, et al. Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry* 1996;20:729-735.
- Barkai A, Dunner D, Gross H, et al. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. *Biol Psychiatry* 1978;13:65-72.
- Belmaker RH, Bersudsky Y, Agam G, et al. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. *Annu Rev Med* 1996;47:47-56. (Review)
- Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. *Am J Psychiatry* 1995;152(7):1084-1086.
- Benjamin J, Agam G, Levine J, et al. Inositol treatment in psychiatry. *Psychopharmacol Bull* 1995;31(1):167-175. (Review)
- Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. *Am J Psychiatry* 1995;152:1084-1086.
- Bersudsky Y, Einat H, Stahl Z, et al. Epi-inositol and inositol depletion: two new treatment approaches in affective disorder. *Curr Psychiatry Rep* 1999;1(2):141-147.
- Carey PD, Warwick J, Harvey BH, et al. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. *Metab Brain Dis* 2004;19(1-2):125-134.
- Chengappa KN, Levine J, Gershon S, et al. Inositol as an add-on treatment for bipolar depression. *Bipolar Disord* 2000;2(1):47-55.
- Cohen H, Kotler M, Kaplan Z, et al. Inositol has behavioral effects with adaptation after chronic administration. *J Neural Transm* 1997;104:299-305.
- Colodny L, Hoffman RL. Inositol: clinical applications for exogenous use. *Altern Med Rev* 1998;3(6):432-447. (Review)
- Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. *JPEN J Parenter Enteral Nutr* 1997;21(6):357-365. (Review)
- Dong Z, Huang C, Ma WY. PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer. *Anticancer Res* 1999;19:3743-3747.
- Dow B, Kline N. Antidepressant treatment of post traumatic stress disorder and major depression in veterans. *Ann Clin Psychiatry* 1997;9:1-5.
- Downes CP. The cellular functions of myo-inositol. *Biochem Soc Trans* 1989;17:259-268.
- Einat H, Belmaker RH, Kopilov M, et al. Rat brain monamines after acute and chronic myo-inositol treatment. *Eur Neuropsychopharmacol* 1999;10:27-30.
- Einat H, Clenet F, Shaldubina A, et al. The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. *Behav Brain Res* 2001;118(1):77-83.
- Einat H, Karbovski H, Korik J, et al. Inositol reduces depressive-like behaviors in two different models of depression. *Psychopharmacology* 1999;144:158-162.
- Flament M, Bissler J. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. *J Clin Psychiatry* 1997;58:18-22.
- Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. *Int J Neuropsychopharmacol* 1999;2(3):193-195.
- Fux M, Levine J, Aviv A, et al. Inositol treatment of obsessive-compulsive disorder. *Am J Psychiatry* 1996;153(9):1219-1221.
- Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eating. *Int J Eat Disord* 2001;29(3):345-348.
- Greene N, Copp A. Inositol prevents folate-resistant neural tube defects in the mouse. *Nat Med* 1997;3:60-66.
- Gregersen G, Bertelsen B, Harbo H, et al. Oral supplementation of myo-inositol: effects on peripheral nerve function in human diabetics and on the concentration in plasma, erythrocytes, urine and muscle tissue in human diabetics and normals. *Acta Neurol Scand* 1983;67:164-172.
- Hallman M, Bry K, Hoppu K, et al. Inositol supplementation in premature infants with respiratory distress syndrome. *N Engl J Med* 1992;326:1233-1239.
- Harvey BH, Brink CB, Seedat S, et al. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26(1):21-32. (Review)
- Harvey BH, Scheepers A, Brand L, et al. Chronic inositol increases striatal D(2) receptors but does not modify dexamphetamine-induced motor behavior: relevance to obsessive-compulsive disorder. *Pharmacol Biochem Behav* 2001;68(2):245-253.
- Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. *Annu Rev Nutr* 1986;6:563-597.

Citations and Reference Literature: Inositol

- Holub BJ. The cellular forms and functions of the inositol phospholipids and their metabolic derivatives. *Nutr Rev* 1987;45:65-71.
- Holub BJ. The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and disease. *Adv Nutr Res* 1982;4:107-141.
- Hooper N. Glycosyl-phosphatidylinositol anchored membrane enzymes. *Clin Chim Acta* 1997;266:3-12.
- Ishikawa T, Nakatsuru Y, Zarkovic M, et al. Inhibition of skin cancer by IP6 in vivo: initiation-promotion model. *Anticancer Res* 1999;19(5A):3749-3752.
- Johnson EC, Gray-Keller MP, O'Day PM. Rescue of excitation by inositol following Li(+)-induced block in *Limulus* ventral photoreceptors. *Vis Neurosci* 1998;15(1):105-112.
- Jope R, Song L, Grimes C, et al. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. *J Neurochem* 1998;70:763-771.
- Kaplan Z, Amir M, Swartz M, et al. Inositol treatment of post traumatic stress disorder. *Anxiety* 1996;2:51-52.
- Kato T, Inubushi T, Kato N. Prediction of lithium response by 31P-MRS in bipolar disorder. *Int J Neuropsychopharmacol* 2000;3(1):83-85.
- Khandelwal M, Reece EA, Wu YK, et al. Dietary myo-inositol therapy in hyperglycemic-induced embryopathy. *Teratology* 1998;57:79-84.
- Kofman O, Belmaker RH. Ziskind-Somerfeld Research Award 1993: biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. *Biol Psychiatry* 1993;34(12):839-852.
- Larner J, Allan G, Kessler C, et al. Phosphoinositide glycan derived mediators and insulin resistance: prospects for diagnosis and therapy. *J Basic Clin Physiol Pharmacol* 1998;9:127-137.
- Levine J. Controlled trials of inositol in psychiatry. *Eur Neuropsychopharmacol* 1997;7:147-155.
- Levine J, Aviram A, Holan A, et al. Inositol treatment of autism. *J Neural Transm* 1997;104:307-310.
- Levine J, Barak Y, Gonzales M, et al. Double-blind, controlled trial of inositol treatment of depression. *Am J Psychiatry* 1995;152:792-794.
- Levine J, Barak Y, Kofman O, et al. Follow-up and relapse of an inositol study of depression. *Isr J Psychiatry Relat Sci* 1995;32:14-21.
- Levine J, Goldberger I, Rapoport A, et al. CSF inositol in schizophrenia and high dose inositol treatment of schizophrenia. *Eur Neuropsychopharmacol* 1994;4:487-490.
- Levine J, Kurtzman L, Rapoport A, et al. CSF inositol does not predict antidepressant response to inositol. *J Neural Transm* 1996;103:1457-1462.
- Levine J, Rapoport A, Lev L, et al. Inositol treatment raises CSF inositol levels. *Brain Res* 1993;627:168-169.
- Levine J, Ring A, Barak Y, et al. Inositol may worsen attention deficit disorder with hyperactivity. *Hum Psychopharmacol* 1995;10:481-484.
- Levine J, Umansky R, Ezrielev G, et al. Lack of effect of inositol treatment in chronic schizophrenia. *Biol Psychiatry* 1993;33:673-675.
- Levine J, Witztum E, Greenberg BD, et al. Inositol-induced mania? *Am J Psychiatry* 1996;153:839. (Letter)
- Moorman JM, Leslie RA. Paradoxical effects of lithium on serotonergic receptor function: an immunocytochemical, behavioural and autoradiographic study. *Neuropharmacology* 1998;37(3):357-374.
- Nemets B, Talesnick B, Belmaker RH, et al. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. *World J Biol Psychiatry* 2002;3:147-149.
- Nestler JE, Jakabowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. *N Engl J Med* 1999;340:1314-1320.
- Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. *J Nutr* 2002;132(8 Suppl):2333S-2335S.
- Palatnik A, Frolov K, Fux M, et al. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. *J Clin Psychopharmacol* 2001;21(3):335-339.
- Pandey GN, Ren X, Pandey SC, et al. Hyperactive phosphoinositide signaling pathway in platelets of depressed patients: effect of desipramine treatment. *Psychiatry Res* 2001;105(1-2):23-32.
- Penzel F. Inositol and trichotillomania. Available at <http://westsuffolkpsych.homestead.com/Inositol.html>. Accessed October 18, 2002.
- Reece E, Khandelwal M, Wu YK, et al. Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. *Am J Obstet Gynecol* 1997;176:536-539.
- Salway JG, Whitehead L, Finnegan JA, et al. Effect of myo-inositol on peripheral-nerve function in diabetes. *Lancet* 1978;2(8103):1282-1284.
- Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. *Int Clin Psychopharmacol* 1999;14:353-356.

Citations and Reference Literature: Inositol

- Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. *Life Sci* 1997;61:343-354.
- Shamsuddin AM. Metabolism and cellular functions of IP6: a review. *Anticancer Res* 1999;19(5A):3733-3736.
- Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. *Anticancer Res* 1999;19(5A):3671-3674.
- Siener R, Hesse A. The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation. *Eur J Nutr* 2003;42(6):332-337.
- Tarnow P, Cassuto J, Jonsson A, et al. Postoperative analgesia by D-myo-inositol-1,2,6-triphosphate in patients undergoing cholecystectomy. *Anesth Analg* 1998;86:107-110.
- Thompson G, Kalid N. Inositol therapy of neonatal respiratory distress syndrome. *Micromedix* 1997:97.
- Tricklebank MD, Singh L, Jackson A, et al. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. *Brain Res* 1991;558(1):145-148.
- Vandal R. Role of inositol in the treatment of psychiatric disorders. *CNS Drugs* 1997;7:6-16.
- van Minnen A, Hoogduin KA, Keijsers GP, et al. Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. *Arch Gen Psychiatry* 2003;60(5):517-522.
- Vucenik I, Kalebic T, Tantivejkul K, et al. Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. *Anticancer Res* 1998;18(3A):1377-1384.
- Wattenberg LW. Chemoprevention of pulmonary carcinogenesis by myo-inositol. *Anticancer Res* 1999;19:3659-3661.
- Yang GY, Shamsuddin AM. IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. *Anticancer Res* 1995;15:2479-2487.